



## **Diana Santos**

Associate

Willkie Farr & Gallagher LLP

---

Diana Santos is an associate in the Intellectual Property Department. She has advised major technology, automotive, pharmaceutical, consumer product, and medical device companies in the development of offensive and defensive legal strategies. Diana has experience in a variety of patent litigation stages, and has represented clients in various forums, including district courts, the International Trade Commission, the Patent Trial and Appeal Board, and the American Arbitration Association. She has counseled clients on IP issues in licensing, research and development, and acquisition agreements and investments. Also, Diana has advised clients on branding, trademark, and copyright issues and conducted strategic investigations concerning advertisements and consumer law.

Diana is a member of the LatinoJustice PRLDEF Líderes Board and the Hispanic National Bar Association's Young Lawyer's Division former President. Diana is also a member of the New York Intellectual Property Law Association's Programs Committee.



## **Eugene L. Chang**

Partner

Willkie Farr & Gallagher LLP

---

Eugene Chang is a partner in the Intellectual Property Department. He is an intellectual property litigator and licensing attorney who practices on the cutting edge of intellectual property, antitrust and bankruptcy law. He litigates intellectual property issues in the United States and internationally across a wide range of technology areas. He also counsels clients on intellectual property and technology services issues arising in complex transactions, like private equity, insurance mergers and acquisitions, public and private offerings, bankruptcy-related acquisitions and standards-related licensing programs.

Eugene was named to the 2012 BTI Client Service All-Star Team, an elite group of attorneys recognized by leading corporate counsel for delivering superior client service.



**Robert M. Isackson**  
Partner  
Venable LLP - New York, NY

---

Rob Isackson is a partner in Venable's Intellectual Property Litigation practice and an experienced first chair trial attorney with a winning track record of resolving complex intellectual property disputes. His experience also includes trademark, trade dress, and copyright litigation, IP transactions, due diligence investigation, opinions, and strategic counseling.

With a focus on patent and trade secret disputes and commercial disputes over technology issues, Mr. Isackson has served as lead counsel in more than 40 federal cases, and appears regularly in proceedings before the Patent and Trademark Office and international arbitration tribunals.

#### **EDUCATION**

J.D., University of Michigan Law School

B.S.E., magna cum laude, University of Michigan

137 S.Ct. 1523  
Supreme Court of the United States  
IMPRESSION PRODUCTS, INC., Petitioner  
v.  
LEXMARK INTERNATIONAL, INC.

No. 15–1189.

|  
Argued March 21, 2017.

|  
Decided May 30, 2017.

**Synopsis**

**Background:** Patentee brought action alleging that competitor infringed its patents related to toner cartridges by refurbishing and reselling cartridges that patentee had sold in United States, and by importing cartridges that patentee had sold abroad. The United States District Court for the Southern District of Ohio, [Michael R. Barrett, J., 9 F.Supp.3d 830](#), entered an order denying competitor's motion to dismiss with respect to cartridges that had been sold abroad, and subsequently entered an order granting competitor's motion to dismiss with respect to cartridges that had been sold domestically, [2014 WL 1276133](#). Parties appealed. The United States Court of Appeals for the Federal Circuit, en banc, Taranto, Circuit Judge, [816 F.3d 721](#), affirmed in part, reversed in part, and remanded. Certiorari was granted.

**Holdings:** The Supreme Court, Chief Justice [Roberts](#), held that:

[1] patentee exhausted its patent rights with respect to domestically sold cartridges, abrogating [Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700](#), and

[2] patentee exhausted its patent rights with respect to internationally sold cartridges, abrogating [Jazz Photo Corp. v. International Trade Commission, 264 F.3d 1094](#), [Dickerson v. Tinning, 84 F. 192](#), [Dickerson v. Matheson, 57 F. 524](#).

Reversed and remanded.

Justice [Ginsburg](#) filed an opinion concurring in part and dissenting in part.

Justice [Gorsuch](#) took no part in the consideration or decision of the case.

**\*1525 Syllabus\***

A United States patent entitles the patent holder to “exclude others from making, using, offering for sale, or selling [its] invention throughout the United States or importing the invention into the United States.” [35 U.S.C. § 154\(a\)](#). Whoever engages in one of these acts “without authority” from the patentee may face liability for patent infringement. [§ 271\(a\)](#). When a patentee sells one of its products, however, the patentee can no longer control that item through the patent laws—its patent rights are said to “exhaust.”

Respondent Lexmark International, Inc. designs, manufactures, and sells toner cartridges to consumers in the United States and abroad. It owns a number of patents that cover components of those cartridges and the manner in which they are used. When Lexmark sells toner cartridges, it gives consumers two options: One option is to buy a toner cartridge at full price, with no restrictions. The other option is to buy a cartridge at a discount through Lexmark's “Return Program.” In exchange for the lower price, customers who buy through the Return Program must sign a contract agreeing to use the cartridge only once and to refrain from transferring the cartridge to anyone but Lexmark.

Companies known as remanufacturers acquire empty Lexmark toner cartridges—including Return Program cartridges—from purchasers in the United States, refill them with toner, and then resell them. They do the same with Lexmark cartridges that they acquire from purchasers overseas and import into the United States. Lexmark sued a number of these remanufacturers, including petitioner Impression Products, Inc., for patent infringement with respect to two groups of cartridges. The first group consists of Return Program cartridges that Lexmark had sold within the United States. Lexmark argued that, because it expressly prohibited reuse and resale of these cartridges, Impression Products infringed the Lexmark patents when it refurbished and resold them. The second group consists of all toner cartridges that

Lexmark had sold abroad and that Impression Products imported into the country. Lexmark claimed that it never gave anyone authority to import these cartridges, so Impression Products infringed its patent rights by doing just that.

**\*1526** Impression Products moved to dismiss on the grounds that Lexmark's sales, both in the United States and abroad, exhausted its patent rights in the cartridges, so Impression Products was free to refurbish and resell them, and to import them if acquired overseas. The District Court granted the motion to dismiss as to the domestic Return Program cartridges, but denied the motion as to the cartridges sold abroad. The Federal Circuit then ruled for Lexmark with respect to both groups of cartridges. Beginning with the Return Program cartridges that Lexmark sold domestically, the Federal Circuit held that a patentee may sell an item and retain the right to enforce, through patent infringement lawsuits, clearly communicated, lawful restrictions on post-sale use or resale. Because Impression Products knew about Lexmark's restrictions and those restrictions did not violate any laws, Lexmark's sales did not exhaust its patent rights, and it could sue Impression Products for infringement. As for the cartridges that Lexmark sold abroad, the Federal Circuit held that, when a patentee sells a product overseas, it does not exhaust its patent rights over that item. Lexmark was therefore free to sue for infringement when Impression Products imported cartridges that Lexmark had sold abroad. Judge Dyk, joined by Judge Hughes, dissented.

*Held* :

1. Lexmark exhausted its patent rights in the Return Program cartridges that it sold in the United States. A patentee's decision to sell a product exhausts all of its patent rights in that item, regardless of any restrictions the patentee purports to impose. As a result, even if the restrictions in Lexmark's contracts with its customers were clear and enforceable under contract law, they do not entitle Lexmark to retain patent rights in an item that it has elected to sell. Pp. 1531 – 1536.

(a) The Patent Act grants patentees the “right to exclude others from making, using, offering for sale, or selling [their] invention[s].” 35 U.S.C. § 154(a). For over 160 years, the doctrine of patent exhaustion has imposed a limit on that right to exclude: When a patentee sells

an item, that product “is no longer within the limits of the [patent] monopoly” and instead becomes the “private, individual property” of the purchaser. *Bloomer v. McQuewan*, 14 How. 539, 549–550, 14 L.Ed. 532. If the patentee negotiates a contract restricting the purchaser's right to use or resell the item, it may be able to enforce that restriction as a matter of contract law, but may not do so through a patent infringement lawsuit.

The exhaustion rule marks the point where patent rights yield to the common law principle against restraints on alienation. The Patent Act promotes innovation by allowing inventors to secure the financial rewards for their inventions. Once a patentee sells an item, it has secured that reward, and the patent laws provide no basis for restraining the use and enjoyment of the product. Allowing further restrictions would run afoul of the “common law's refusal to permit restraints on the alienation of chattels.” *Kirtsaeng v. John Wiley & Sons, Inc.*, 568 U.S. 519, 538, 133 S.Ct. 1351, 185 L.Ed.2d 392. As Lord Coke put it in the 17th century, if an owner restricts the resale or use of an item after selling it, that restriction “is void, because ... it is against Trade and Traffique, and bargaining and contracting between man and man.” 1 E. Coke, *Institutes of the Laws of England* § 360, p. 223 (1628). Congress enacted and has repeatedly revised the Patent Act against the backdrop of this hostility toward restraints on alienation, which is reflected in the exhaustion doctrine.

**\*1527** This Court accordingly has long held that, even when a patentee sells an item under an express, otherwise lawful restriction, the patentee does not retain patent rights in that product. See, e.g., *Quanta Computer, Inc. v. LG Electronics, Inc.*, 553 U.S. 617, 128 S.Ct. 2109, 170 L.Ed.2d 996. And that well-settled line of precedent allows for only one answer in this case: Lexmark cannot bring a patent infringement suit against Impression Products with respect to the Return Program cartridges sold in the United States because, once Lexmark sold those cartridges, it exhausted its right to control them through the patent laws. Pp. 1531 – 1533.

(b) The Federal Circuit reached a different result because it started from the premise that the exhaustion doctrine is an interpretation of the patent infringement statute, which prohibits anyone from using or selling a patented article “without authority” from the patentee. According to the Federal Circuit, exhaustion reflects a default rule

that selling an item “*presumptively* grant[s] ‘authority’ for the purchaser to use it and resell it.” 816 F.3d 721, 742. But if a patentee withholds some authority by expressly limiting the purchaser’s rights, the patentee may enforce that restriction through patent infringement lawsuits. See *id.*, at 741.

The problem with the Federal Circuit’s logic is that the exhaustion doctrine is not a presumption about the authority that comes along with a sale; it is a limit on the scope of the patentee’s rights. The Patent Act gives patentees a limited exclusionary power, and exhaustion extinguishes that power. A purchaser has the right to use, sell, or import an item because those are the rights that come along with ownership, not because it purchased authority to engage in those practices from the patentee. Pp. 1533 – 1536.

2. Lexmark also sold toner cartridges abroad, which Impression Products acquired from purchasers and imported into the United States. Lexmark cannot sue Impression Products for infringement with respect to these cartridges. An authorized sale outside the United States, just as one within the United States, exhausts all rights under the Patent Act.

The question about international exhaustion of intellectual property rights has arisen in the context of copyright law. Under the first sale doctrine, when a copyright owner sells a lawfully made copy of its work, it loses the power to restrict the purchaser’s right “to sell or otherwise dispose of ... that copy.” 17 U.S.C. § 109(a). In *Kirtsaeng v. John Wiley & Sons, Inc.*, 568 U.S. 519, 133 S.Ct. 1351, 185 L.Ed.2d 392, this Court held that the first sale doctrine applies to copies of works made and sold abroad. Central to that decision was the fact that the first sale doctrine has its roots in the common law principle against restraints on alienation. Because that principle makes no geographical distinctions and the text of the Copyright Act did not provide such a distinction, a straightforward application of the first sale doctrine required concluding that it applies overseas.

Applying patent exhaustion to foreign sales is just as straightforward. Patent exhaustion, too, has its roots in the antipathy toward restraints on alienation, and nothing in the Patent Act shows that Congress intended to confine that principle to domestic sales. Differentiating between the patent exhaustion and copyright first sale doctrines

would also make little theoretical or practical sense: The two share a “strong similarity ... and identity of purpose,” *Bauer & Cie v. O'Donnell*, 229 U.S. 1, 13, 33 S.Ct. 616, 57 L.Ed. 1041, and many everyday products are subject to both patent and copyright protections.

**\*1528** Lexmark contends that a foreign sale does not exhaust patent rights because the Patent Act limits a patentee’s power to exclude others from making, using, selling, or importing its products to acts that occur in the United States. Because those exclusionary powers do not apply abroad, the patentee may not be able to sell its products overseas for the same price as it could in the United States, and therefore is not sure to receive the reward guaranteed by American patent laws. Without that reward, says Lexmark, there should be no exhaustion.

The territorial limit on patent rights is no basis for distinguishing copyright protections; those do not have extraterritorial effect either. Nor does the territorial limit support Lexmark’s argument. Exhaustion is a distinct limit on the patent grant, which is triggered by the patentee’s decision to give a patented item up for whatever fee it decides is appropriate. The patentee may not be able to command the same amount for its products abroad as it does in the United States. But the Patent Act does not guarantee a particular price. Instead, the Patent Act just ensures that the patentee receives one reward—of whatever it deems to be satisfactory compensation—for every item that passes outside the scope of its patent monopoly.

This Court’s decision in *Boesch v. Graff*, 133 U.S. 697, 10 S.Ct. 378, 33 L.Ed. 787, is not to the contrary. That decision did not, as Lexmark contends, exempt all foreign sales from patent exhaustion. Instead, it held that a sale abroad does not exhaust a patentee’s rights when the patentee had nothing to do with the transaction. That just reaffirms the basic premise that only the patentee can decide whether to make a sale that exhausts its patent rights in an item.

Finally, the United States advocates what it views as a middle-ground position: that a foreign sale exhausts patent rights unless the patentee expressly reserves those rights. This express-reservation rule is based on the idea that overseas buyers expect to be able to use and resell items freely, so exhaustion should be the presumption. But, at the same time, lower courts have

long allowed patentees to expressly reserve their rights, so that option should remain open to patentees. The sparse and inconsistent decisions the Government cites, however, provide no basis for any expectation, let alone a settled one, that patentees can reserve rights when they sell abroad. The theory behind the express-reservation rule also wrongly focuses on the expectations of the patentee and purchaser during a sale. More is at stake when it comes to patent exhaustion than the dealings between the parties, which can be addressed through contracts. Instead, exhaustion occurs because allowing patent rights to stick to an already-sold item as it travels through the market would violate the principle against restraints on alienation. As a result, restrictions and location are irrelevant for patent exhaustion; what matters is the patentee's decision to make a sale. Pp. 1535 – 1538.

816 F.3d 721, reversed and remanded.

ROBERTS, C.J., delivered the opinion of the Court, in which KENNEDY, THOMAS, BREYER, ALITO, SOTOMAYOR, and KAGAN, JJ., joined. GINSBURG, J., filed an opinion concurring in part and dissenting in part. GORSUCH, J., took no part in the consideration or decision of the case.

#### Attorneys and Law Firms

Andrew J. Pincus, Washington, DC, for Petitioner.

Malcolm L. Stewart, Washington, DC, for the United States as amicus curiae, by special leave of the Court, supporting reversal in part and vacatur in part.

\*1529 Constantine L. Trela, Jr., Chicago, IL, for Respondent.

Edward F. O'Connor, Avyno Law, Encino, CA, Andrew J. Pincus, Paul W. Hughes, Matthew A. Waring, John T. Lewis, Karianne M. Jones, Mayer Brown LLP, Washington, DC, for Petitioner.

Timothy C. Meece, V. Bryan Medlock, Jr., Jason S. Shull, Audra C. Eidem Heinze, Banner & Witcoff, Ltd., Chicago, IL, Steven B. Loy, Stoll Keenon Ogden PLLC, Lexington, KY, Constantine L. Trela, Jr., Robert N. Hochman, Sidley Austin LLP, Chicago, IL, Benjamin Beaton, Joshua J. Fougere, Sidley Austin LLP, Washington, DC, D. Brent Lambert, Lexmark Int'l, Inc., Lexington, KY, for Respondent.

For U.S. Supreme Court briefs, see:

#### Opinion

Chief Justice ROBERTS delivered the opinion of the Court.

A United States patent entitles the patent holder (the “patentee”), for a period of 20 years, to “exclude others from making, using, offering for sale, or selling [its] invention throughout the United States or importing the invention into the United States.” 35 U.S.C. § 154(a). Whoever engages in one of these acts “without authority” from the patentee may face liability for patent infringement. § 271(a).

When a patentee sells one of its products, however, the patentee can no longer control that item through the patent laws—its patent rights are said to “exhaust.” The purchaser and all subsequent owners are free to use or resell the product just like any other item of personal property, without fear of an infringement lawsuit.

This case presents two questions about the scope of the patent exhaustion doctrine: First, whether a patentee that sells an item under an express restriction on the purchaser's right to reuse or resell the product may enforce that restriction through an infringement lawsuit. And second, whether a patentee exhausts its patent rights by selling its product outside the United States, where American patent laws do not apply. We conclude that a patentee's decision to sell a product exhausts all of its patent rights in that item, regardless of any restrictions the patentee purports to impose or the location of the sale.

#### I

The underlying dispute in this case is about laser printers—or, more specifically, the cartridges that contain the powdery substance, known as toner, that laser printers use to make an image appear on paper. Respondent Lexmark International, Inc. designs, manufactures, and sells toner cartridges to consumers in the United States and around the globe. It owns a number of patents that cover components of those cartridges and the manner in which they are used.

When toner cartridges run out of toner they can be refilled and used again. This creates an opportunity for other companies—known as remanufacturers—to acquire empty Lexmark cartridges from purchasers in the United States and abroad, refill them with toner, and then resell them at a lower price than the new ones Lexmark puts on the shelves.

Not blind to this business problem, Lexmark structures its sales in a way that encourages customers to return spent cartridges. It gives purchasers two options: One is to buy a toner cartridge at full price, with no strings attached. The other is to buy a cartridge at roughly 20–percent \*1530 off through Lexmark's "Return Program." A customer who buys through the Return Program still owns the cartridge but, in exchange for the lower price, signs a contract agreeing to use it only once and to refrain from transferring the empty cartridge to anyone but Lexmark. To enforce this single-use/no-resale restriction, Lexmark installs a microchip on each Return Program cartridge that prevents reuse once the toner in the cartridge runs out.

Lexmark's strategy just spurred remanufacturers to get more creative. Many kept acquiring empty Return Program cartridges and developed methods to counteract the effect of the microchips. With that technological obstacle out of the way, there was little to prevent the remanufacturers from using the Return Program cartridges in their resale business. After all, Lexmark's contractual single-use/no-resale agreements were with the initial customers, not with downstream purchasers like the remanufacturers.

Lexmark, however, was not so ready to concede that its plan had been foiled. In 2010, it sued a number of remanufacturers, including petitioner Impression Products, Inc., for patent infringement with respect to two groups of cartridges. One group consists of Return Program cartridges that Lexmark sold within the United States. Lexmark argued that, because it expressly prohibited reuse and resale of these cartridges, the remanufacturers infringed the Lexmark patents when they refurbished and resold them. The other group consists of all toner cartridges that Lexmark sold abroad and that remanufacturers imported into the country. Lexmark claimed that it never gave anyone authority to import these cartridges, so the remanufacturers ran afoul of its patent rights by doing just that.

Eventually, the lawsuit was whittled down to one defendant, Impression Products, and one defense: that Lexmark's sales, both in the United States and abroad, exhausted its patent rights in the cartridges, so Impression Products was free to refurbish and resell them, and to import them if acquired abroad. Impression Products filed separate motions to dismiss with respect to both groups of cartridges. The District Court granted the motion as to the domestic Return Program cartridges, but denied the motion as to the cartridges Lexmark sold abroad. Both parties appealed.

The Federal Circuit considered the appeals en banc and ruled for Lexmark with respect to both groups of cartridges. The court began with the Return Program cartridges that Lexmark sold in the United States. Relying on its decision in *Mallinckrodt, Inc. v. Medipart, Inc.*, 976 F.2d 700 (1992), the Federal Circuit held that a patentee may sell an item and retain the right to enforce, through patent infringement lawsuits, "clearly communicated, ... lawful restriction[s] as to post-sale use or resale." 816 F.3d 721, 735 (2016). The exhaustion doctrine, the court reasoned, derives from the prohibition on making, using, selling, or importing items "without authority." *Id.*, at 734 (quoting 35 U.S.C. § 271(a)). When you purchase an item you presumptively also acquire the authority to use or resell the item freely, but that is just a presumption; the same authority does not run with the item when the seller restricts post-sale use or resale. 816 F.3d, at 742. Because the parties agreed that Impression Products knew about Lexmark's restrictions and that those restrictions did not violate any laws, the Federal Circuit concluded that Lexmark's sales had not exhausted all of its patent rights, and that the company could sue for infringement when Impression Products refurbished \*1531 and resold Return Program cartridges.

As for the cartridges that Lexmark sold abroad, the Federal Circuit once again looked to its precedent. In *Jazz Photo Corp. v. International Trade Commission*, 264 F.3d 1094 (2001), the court had held that a patentee's decision to sell a product abroad did not terminate its ability to bring an infringement suit against a buyer that "import[ed] the article and [sold] ... it in the United States." 816 F.3d, at 726–727. That rule, the court concluded, makes good sense: Exhaustion is justified when a patentee receives "the reward available from [selling in] American markets," which does not occur when the patentee sells overseas, where the American patent offers no protection and

therefore cannot bolster the price of the patentee's goods. *Id.*, at 760–761. As a result, Lexmark was free to exercise its patent rights to sue Impression Products for bringing the foreign-sold cartridges to market in the United States.

Judge Dyk, joined by Judge Hughes, dissented. In their view, selling the Return Program cartridges in the United States exhausted Lexmark's patent rights in those items because any “authorized sale of a patented article ... free[s] the article from any restrictions on use or sale based on the patent laws.” *Id.*, at 775–776. As for the foreign cartridges, the dissenters would have held that a sale abroad also results in exhaustion, unless the seller “explicitly reserve[s] [its] United States patent rights” at the time of sale. *Id.*, at 774, 788. Because Lexmark failed to make such an express reservation, its foreign sales exhausted its patent rights.

We granted certiorari to consider the Federal Circuit's decisions with respect to both domestic and international exhaustion, 580 U.S. —, 137 S.Ct. 546, 196 L.Ed.2d 442 (2016), and now reverse.

## II

### A

[1] First up are the Return Program cartridges that Lexmark sold in the United States. We conclude that Lexmark exhausted its patent rights in these cartridges the moment it sold them. The single-use/no-resale restrictions in Lexmark's contracts with customers may have been clear and enforceable under contract law, but they do not entitle Lexmark to retain patent rights in an item that it has elected to sell.

[2] [3] The Patent Act grants patentees the “right to exclude others from making, using, offering for sale, or selling [their] invention[s].” 35 U.S.C. § 154(a). For over 160 years, the doctrine of patent exhaustion has imposed a limit on that right to exclude. See *Bloomer v. McQuewan*, 14 How. 539, 14 L.Ed. 532 (1853). The limit functions automatically: When a patentee chooses to sell an item, that product “is no longer within the limits of the monopoly” and instead becomes the “private, individual property” of the purchaser, with the rights and benefits that come along with ownership. *Id.*, at 549–550. A patentee is free to set the price and negotiate contracts with purchasers, but may not, “by virtue of his

*patent*, control the use or disposition” of the product after ownership passes to the purchaser. *United States v. Univis Lens Co.*, 316 U.S. 241, 250, 62 S.Ct. 1088, 86 L.Ed. 1408 (1942) (emphasis added). The sale “terminates all patent rights to that item.” *Quanta Computer, Inc. v. LG Electronics, Inc.*, 553 U.S. 617, 625, 128 S.Ct. 2109, 170 L.Ed.2d 996 (2008).

[4] [5] This well-established exhaustion rule marks the point where patent rights yield to the common law principle against restraints on alienation. The Patent Act \*1532 “promote[s] the progress of science and the useful arts by granting to [inventors] a limited monopoly” that allows them to “secure the financial rewards” for their inventions. *Univis*, 316 U.S., at 250, 62 S.Ct. 1088. But once a patentee sells an item, it has “enjoyed all the rights secured” by that limited monopoly. *Keeler v. Standard Folding Bed Co.*, 157 U.S. 659, 661, 15 S.Ct. 738, 39 L.Ed. 848 (1895). Because “the purpose of the patent law is fulfilled ... when the patentee has received his reward for the use of his invention,” that law furnishes “no basis for restraining the use and enjoyment of the thing sold.” *Univis*, 316 U.S., at 251, 62 S.Ct. 1088.

We have explained in the context of copyright law that exhaustion has “an impeccable historic pedigree,” tracing its lineage back to the “common law's refusal to permit restraints on the alienation of chattels.” *Kirtsaeng v. John Wiley & Sons, Inc.*, 568 U.S. 519, 538, 133 S.Ct. 1351, 185 L.Ed.2d 392 (2013). As Lord Coke put it in the 17th century, if an owner restricts the resale or use of an item after selling it, that restriction “is void, because ... it is against Trade and Traffique, and bargaining and contracting between man and man.” 1 E. Coke, *Institutes of the Laws of England* § 360, p. 223 (1628); see J. Gray, *Restraints on the Alienation of Property* § 27, p. 18 (2d ed. 1895) (“A condition or conditional limitation on alienation attached to a transfer of the entire interest in personalty is as void as if attached to a fee simple in land”).

[6] This venerable principle is not, as the Federal Circuit dismissively viewed it, merely “one common-law jurisdiction's general judicial policy at one time toward anti-alienation restrictions.” 816 F.3d, at 750. Congress enacted and has repeatedly revised the Patent Act against the backdrop of the hostility toward restraints on alienation. That enmity is reflected in the exhaustion doctrine. The patent laws do not include the right to “restrain [ ] ... further alienation” after an initial sale; such

conditions have been “hateful to the law from Lord Coke’s day to ours” and are “obnoxious to the public interest.” *Straus v. Victor Talking Machine Co.*, 243 U.S. 490, 501, 37 S.Ct. 412, 61 L.Ed. 866 (1917). “The inconvenience and annoyance to the public that an opposite conclusion would occasion are too obvious to require illustration.” *Keeler*, 157 U.S., at 667, 15 S.Ct. 738.

But an illustration never hurts. Take a shop that restores and sells used cars. The business works because the shop can rest assured that, so long as those bringing in the cars own them, the shop is free to repair and resell those vehicles. That smooth flow of commerce would sputter if companies that make the thousands of parts that go into a vehicle could keep their patent rights after the first sale. Those companies might, for instance, restrict resale rights and sue the shop owner for patent infringement. And even if they refrained from imposing such restrictions, the very threat of patent liability would force the shop to invest in efforts to protect itself from hidden lawsuits. Either way, extending the patent rights beyond the first sale would clog the channels of commerce, with little benefit from the extra control that the patentees retain. And advances in technology, along with increasingly complex supply chains, magnify the problem. See Brief for Costco Wholesale Corp. et al. as *Amici Curiae* 7–9; Brief for Intel Corp. et al. as *Amici Curiae* 17, n. 5 (“A generic smartphone assembled from various high-tech components could practice an estimated 250,000 patents”).

[7] This Court accordingly has long held that, even when a patentee sells an item under an express restriction, the patentee does not retain patent rights in that \*1533 product. In *Boston Store of Chicago v. American Graphophone Co.*, for example, a manufacturer sold graphophones—one of the earliest devices for recording and reproducing sounds—to retailers under contracts requiring those stores to resell at a specific price. 246 U.S. 8, 17–18, 38 S.Ct. 257, 62 L.Ed. 551 (1918). When the manufacturer brought a patent infringement suit against a retailer who sold for less, we concluded that there was “no room for controversy” about the result: By selling the item, the manufacturer placed it “beyond the confines of the patent law, [and] could not, by qualifying restrictions as to use, keep [it] under the patent monopoly.” *Id.*, at 20, 25, 38 S.Ct. 257.

Two decades later, we confronted a similar arrangement in *United States v. Univis Lens Co.* There, a company that made eyeglass lenses authorized an agent to sell its products to wholesalers and retailers only if they promised to market the lenses at fixed prices. The Government filed an antitrust lawsuit, and the company defended its arrangement on the ground that it was exercising authority under the Patent Act. We held that the initial sales “relinquish [ed] ... the patent monopoly with respect to the article[s] sold,” so the “stipulation ... fixing resale prices derive[d] no support from the patent and must stand on the same footing” as restrictions on unpatented goods. 316 U.S., at 249–251, 62 S.Ct. 1088.

It is true that *Boston Store* and *Univis* involved resale price restrictions that, at the time of those decisions, violated the antitrust laws. But in both cases it was the sale of the items, rather than the illegality of the restrictions, that prevented the patentees from enforcing those resale price agreements through patent infringement suits. And if there were any lingering doubt that patent exhaustion applies even when a sale is subject to an express, otherwise lawful restriction, our recent decision in *Quanta Computer, Inc. v. LG Electronics, Inc.* settled the matter. In that case, a technology company—with authorization from the patentee—sold microprocessors under contracts requiring purchasers to use those processors with other parts that the company manufactured. One buyer disregarded the restriction, and the patentee sued for infringement. Without so much as mentioning the lawfulness of the contract, we held that the patentee could not bring an infringement suit because the “authorized sale ... took its products outside the scope of the patent monopoly.” 553 U.S., at 638, 128 S.Ct. 2109.

Turning to the case at hand, we conclude that this well-settled line of precedent allows for only one answer: Lexmark cannot bring a patent infringement suit against Impression Products to enforce the single-use/no-resale provision accompanying its Return Program cartridges. Once sold, the Return Program cartridges passed outside of the patent monopoly, and whatever rights Lexmark retained are a matter of the contracts with its purchasers, not the patent law.

B

The Federal Circuit reached a different result largely because it got off on the wrong foot. The “exhaustion doctrine,” the court believed, “must be understood as an interpretation of” the infringement statute, which prohibits anyone from using or selling a patented article “without authority” from the patentee. 816 F.3d, at 734 (quoting 35 U.S.C. § 271(a)). Exhaustion reflects a default rule that a patentee’s decision to sell an item “presumptively grant[s] ‘authority’ to the purchaser to use it and resell it.” 816 F.3d, at 742. But, the Federal Circuit explained, the patentee does not have to hand over the full “bundle \*1534 of rights” every time. *Id.*, at 741 (internal quotation marks omitted). If the patentee expressly withholds a stick from the bundle—perhaps by restricting the purchaser’s resale rights—the buyer never acquires that withheld authority, and the patentee may continue to enforce its right to exclude that practice under the patent laws.

[8] [9] The misstep in this logic is that the exhaustion doctrine is not a presumption about the authority that comes along with a sale; it is instead a limit on “the scope of the patentee’s rights.” *United States v. General Elec. Co.*, 272 U.S. 476, 489, 47 S.Ct. 192, 71 L.Ed. 362 (1926) (emphasis added). The right to use, sell, or import an item exists independently of the Patent Act. What a patent adds—and grants exclusively to the patentee—is a limited right to prevent others from engaging in those practices. See *Crown Die & Tool Co. v. Nye Tool & Machine Works*, 261 U.S. 24, 35, 43 S.Ct. 254, 67 L.Ed. 516 (1923). Exhaustion extinguishes that exclusionary power. See *Bloomer*, 14 How., at 549 (the purchaser “exercises no rights created by the act of Congress, nor does he derive title to [the item] by virtue of the ... exclusive privilege granted to the patentee”). As a result, the sale transfers the right to use, sell, or import because those are the rights that come along with ownership, and the buyer is free and clear of an infringement lawsuit because there is no exclusionary right left to enforce.

The Federal Circuit also expressed concern that preventing patentees from reserving patent rights when they sell goods would create an artificial distinction between such sales and sales by licensees. Patentees, the court explained, often license others to make and sell their products, and may place restrictions on those licenses. A computer developer could, for instance, license a manufacturer to make its patented devices and sell them only for non-commercial use by individuals. If a licensee

breaches the license by selling a computer for commercial use, the patentee can sue the licensee for infringement. And, in the Federal Circuit’s view, our decision in *General Talking Pictures Corp. v. Western Elec. Co.*, 304 U.S. 175, 58 S.Ct. 849, 82 L.Ed. 1273, *aff’d on reh’g*, 305 U.S. 124, 59 S.Ct. 116, 83 L.Ed. 81 (1938), established that—when a patentee grants a license “under clearly stated restrictions on post-sale activities” of those who purchase products from the licensee—the patentee can *also* sue for infringement those purchasers who knowingly violate the restrictions. 816 F.3d, at 743–744. If patentees can employ licenses to impose post-sale restrictions on purchasers that are enforceable through infringement suits, the court concluded, it would make little sense to prevent patentees from doing so when they sell directly to consumers.

The Federal Circuit’s concern is misplaced. A patentee can impose restrictions on licensees because a license does not implicate the same concerns about restraints on alienation as a sale. Patent exhaustion reflects the principle that, when an item passes into commerce, it should not be shaded by a legal cloud on title as it moves through the marketplace. But a license is not about passing title to a product, it is about changing the contours of the patentee’s monopoly: The patentee agrees not to exclude a licensee from making or selling the patented invention, expanding the club of authorized producers and sellers. See *General Elec. Co.*, 272 U.S., at 489–490, 47 S.Ct. 192. Because the patentee is exchanging rights, not goods, it is free to relinquish only a portion of its bundle of patent protections.

[10] [11] [12] A patentee’s authority to limit licensees does not, as the Federal Circuit thought, mean that patentees can use licenses \*1535 to impose post-sale restrictions on purchasers that are enforceable through the patent laws. So long as a licensee complies with the license when selling an item, the patentee has, in effect, authorized the sale. That licensee’s sale is treated, for purposes of patent exhaustion, as if the patentee made the sale itself. The result: The sale exhausts the patentee’s rights in that item. See *Hobbie v. Jennison*, 149 U.S. 355, 362–363, 13 S.Ct. 879, 37 L.Ed. 766 (1893). A license may require the licensee to impose a restriction on purchasers, like the license limiting the computer manufacturer to selling for non-commercial use by individuals. But if the licensee does so—by, perhaps, having each customer sign a contract promising not to use the computers in business—the sale nonetheless exhausts all patent rights in the item sold. See

*Motion Picture Patents Co. v. Universal Film Mfg. Co.*, 243 U.S. 502, 506–507, 516, 37 S.Ct. 416, 61 L.Ed. 871 (1917). The purchasers might not comply with the restriction, but the only recourse for the licensee is through contract law, just as if the patentee itself sold the item with a restriction.

[13] *General Talking Pictures* involved a fundamentally different situation: There, a licensee “knowingly ma[de] ... sales ... outside the scope of its license.” 304 U.S., at 181–182, 58 S.Ct. 849 (emphasis added). We treated the sale “as if no license whatsoever had been granted” by the patentee, which meant that the patentee could sue both the licensee and the purchaser—who knew about the breach—for infringement. *General Talking Pictures Corp. v. Western Elec. Co.*, 305 U.S. 124, 127, 59 S.Ct. 116, 83 L.Ed. 81 (1938). This does not mean that patentees can use licenses to impose post-sale restraints on purchasers. Quite the contrary: The licensee infringed the patentee's rights because it did *not* comply with the terms of its license, and the patentee could bring a patent suit against the purchaser only because the purchaser participated in the licensee's infringement. *General Talking Pictures*, then, stands for the modest principle that, if a patentee has not given authority for a licensee to make a sale, that sale cannot exhaust the patentee's rights.

In sum, patent exhaustion is uniform and automatic. Once a patentee decides to sell—whether on its own or through a licensee—that sale exhausts its patent rights, regardless of any post-sale restrictions the patentee purports to impose, either directly or through a license.

### III

[14] [15] Our conclusion that Lexmark exhausted its patent rights when it sold the domestic Return Program cartridges goes only halfway to resolving this case. Lexmark also sold toner cartridges abroad and sued Impression Products for patent infringement for “importing [Lexmark's] invention into the United States.” 35 U.S.C. § 154(a). Lexmark contends that it may sue for infringement with respect to all of the imported cartridges—not just those in the Return Program—because a foreign sale does not trigger patent exhaustion unless the patentee “expressly or implicitly transfer[s] or license[s]” its rights. Brief for Respondent 36–37. The Federal Circuit agreed, but we do not. An authorized sale outside the

United States, just as one within the United States, exhausts all rights under the Patent Act.

[16] This question about international exhaustion of intellectual property rights has also arisen in the context of copyright law. Under the “first sale doctrine,” which is codified at 17 U.S.C. § 109(a), when a copyright owner sells a lawfully made copy of its work, it loses the power to restrict the purchaser's freedom “to sell or otherwise dispose of ... that copy.” In \*1536 *Kirtsaeng v. John Wiley & Sons, Inc.*, we held that this “‘first sale’ [rule] applies to copies of a copyrighted work lawfully made [and sold] abroad.” 568 U.S., at 525, 133 S.Ct. 1351. We began with the text of § 109(a), but it was not decisive: The language neither “restrict [s] the scope of [the] ‘first sale’ doctrine geographically,” nor clearly embraces international exhaustion. *Id.*, at 528–533, 133 S.Ct. 1351. What helped tip the scales for global exhaustion was the fact that the first sale doctrine originated in “the common law's refusal to permit restraints on the alienation of chattels.” *Id.*, at 538, 133 S.Ct. 1351. That “common-law doctrine makes no geographical distinctions.” *Id.*, at 539, 133 S.Ct. 1351. The lack of any textual basis for distinguishing between domestic and international sales meant that “a straightforward application” of the first sale doctrine required the conclusion that it applies overseas. *Id.*, at 540, 133 S.Ct. 1351 (internal quotation marks omitted).

Applying patent exhaustion to foreign sales is just as straightforward. Patent exhaustion, too, has its roots in the antipathy toward restraints on alienation, see *supra*, at 1528 – 1533, and nothing in the text or history of the Patent Act shows that Congress intended to confine that borderless common law principle to domestic sales. In fact, Congress has not altered patent exhaustion at all; it remains an unwritten limit on the scope of the patentee's monopoly. See *Astoria Fed. Sav. & Loan Assn. v. Solimino*, 501 U.S. 104, 108, 111 S.Ct. 2166, 115 L.Ed.2d 96 (1991) (“[W]here a common-law principle is well established, ... courts may take it as given that Congress has legislated with an expectation that the principle will apply except when a statutory purpose to the contrary is evident” (internal quotation marks omitted)). And differentiating the patent exhaustion and copyright first sale doctrines would make little theoretical or practical sense: The two share a “strong similarity ... and identity of purpose,” *Bauer & Cie v. O'Donnell*, 229 U.S. 1, 13, 33 S.Ct. 616, 57 L.Ed. 1041

(1913), and many everyday products—“automobiles, microwaves, calculators, mobile phones, tablets, and personal computers”—are subject to both patent and copyright protections, see *Kirtsaeng*, 568 U.S., at 545, 133 S.Ct. 1351; Brief for Costco Wholesale Corp. et al. as *Amici Curiae* 14–15. There is a “historic kinship between patent law and copyright law,” *Sony Corp. of America v. Universal City Studios, Inc.*, 464 U.S. 417, 439, 104 S.Ct. 774, 78 L.Ed.2d 574 (1984), and the bond between the two leaves no room for a rift on the question of international exhaustion.

Lexmark sees the matter differently. The Patent Act, it points out, limits the patentee's “right to exclude others” from making, using, selling, or importing its products to acts that occur in the United States. 35 U.S.C. § 154(a). A domestic sale, it argues, triggers exhaustion because the sale compensates the patentee for “surrendering [those] U.S. rights.” Brief for Respondent 38. A foreign sale is different: The Patent Act does not give patentees exclusionary powers abroad. Without those powers, a patentee selling in a foreign market may not be able to sell its product for the same price that it could in the United States, and therefore is not sure to receive “the reward guaranteed by U.S. patent law.” *Id.*, at 39 (internal quotation marks omitted). Absent that reward, says Lexmark, there should be no exhaustion. In short, there is no patent exhaustion from sales abroad because there are no patent rights abroad to exhaust.

[17] The territorial limit on patent rights is, however, no basis for distinguishing copyright protections; those protections “do not have any extraterritorial operation” either. 5 M. Nimmer & D. Nimmer, Copyright § 17.02, p. 17–26 (2017). Nor does the territorial limit support the premise of Lexmark's argument. Exhaustion is a separate limit on the patent grant, and does not depend on the patentee receiving some undefined premium for selling the right to access the American market. A purchaser buys an item, not patent rights. And exhaustion is triggered by the patentee's decision to give that item up and receive whatever fee it decides is appropriate “for the article and the invention which it embodies.” *Univis*, 316 U.S., at 251, 62 S.Ct. 1088. The patentee may not be able to command the same amount for its products abroad as it does in the United States. But the Patent Act does not guarantee a particular price, much less the price from selling to American consumers. Instead, the right to exclude just ensures that the patentee receives one

reward—of whatever amount the patentee deems to be “satisfactory compensation,” *Keeler*, 157 U.S., at 661, 15 S.Ct. 738—for every item that passes outside the scope of the patent monopoly.

This Court has addressed international patent exhaustion in only one case, *Boesch v. Graff*, decided over 125 years ago. All that case illustrates is that a sale abroad does not exhaust a patentee's rights when the patentee had nothing to do with the transaction. *Boesch*—from the days before the widespread adoption of electrical lighting—involved a retailer who purchased lamp burners from a manufacturer in Germany, with plans to sell them in the United States. The manufacturer had authority to make the burners under German law, but there was a hitch: Two individuals with no ties to the German manufacturer held the American patent to that invention. These patentees sued the retailer for infringement when the retailer imported the lamp burners into the United States, and we rejected the argument that the German manufacturer's sale had exhausted the American patentees' rights. The German manufacturer had no permission to sell in the United States from the American patentees, and the American patentees had not exhausted their patent rights in the products because they had not sold them to anyone, so “purchasers from [the German manufacturer] could not be thereby authorized to sell the articles in the United States.” 133 U.S. 697, 703, 10 S.Ct. 378, 33 L.Ed. 787 (1890).

[18] Our decision did not, as Lexmark contends, exempt all foreign sales from patent exhaustion. See Brief for Respondent 44–45. Rather, it reaffirmed the basic premise that only the patentee can decide whether to make a sale that exhausts its patent rights in an item. The American patentees did not do so with respect to the German products, so the German sales did not exhaust their rights.

Finally, the United States, as an *amicus*, advocates what it views as a middle-ground position: that “a foreign sale authorized by the U.S. patentee exhausts U.S. patent rights unless those rights are expressly reserved.” Brief for United States 7–8. Its position is largely based on policy rather than principle. The Government thinks that an overseas “buyer's legitimate expectation” is that a “sale conveys all of the seller's interest in the patented article,” so the presumption should be that a foreign sale triggers exhaustion. *Id.*, at 32–33. But, at the same time, “lower courts long ago coalesced around” the rule that “a

patentee's express reservation of U.S. patent rights at the time of a foreign sale will be given effect," so that option should remain open to the patentee. *Id.*, at 22 (emphasis deleted).

The Government has little more than "long ago" on its side. In the 1890s, two \*1538 circuit courts—in cases involving the same company—did hold that patentees may use express restrictions to reserve their patent rights in connection with foreign sales. See *Dickerson v. Tinning*, 84 F. 192, 194–195 (C.A.8 1897); *Dickerson v. Matheson*, 57 F. 524, 527 (C.A.2 1893). But no "coalesc[ing]" ever took place: Over the following hundred-plus years, only a smattering of lower court decisions mentioned this express-reservation rule for foreign sales. See, e.g., *Sanofi, S.A. v. Med-Tech Veterinarian Prods., Inc.*, 565 F.Supp. 931, 938 (D.N.J.1983). And in 2001, the Federal Circuit adopted its blanket rule that foreign sales do not trigger exhaustion, even if the patentee fails to expressly reserve its rights. *Jazz Photo*, 264 F.3d, at 1105. These sparse and inconsistent decisions provide no basis for any expectation, let alone a settled one, that patentees can reserve patent rights when they sell abroad.

The theory behind the Government's express-reservation rule also wrongly focuses on the likely expectations of the patentee and purchaser during a sale. Exhaustion does not arise because of the parties' expectations about how sales transfer patent rights. More is at stake when it comes to patents than simply the dealings between the parties, which can be addressed through contract law. Instead, exhaustion occurs because, in a sale, the patentee elects to give up title to an item in exchange for payment. Allowing patent rights to stick remora-like to that item as it flows through the market would violate the principle against restraints on alienation. Exhaustion does not depend on whether the patentee receives a premium for selling in the United States, or the type of rights that buyers expect to receive. As a result, restrictions and location are irrelevant; what matters is the patentee's decision to make a sale.

\* \* \*

The judgment of the United States Court of Appeals for the Federal Circuit is reversed, and the case is remanded for further proceedings consistent with this opinion.

*It is so ordered.*

Justice **GORSUCH** took no part in the consideration or decision of this case.

Justice **GINSBURG**, concurring in part and dissenting in part.

I concur in the Court's holding regarding domestic exhaustion—a patentee who sells a product with an express restriction on reuse or resale may not enforce that restriction through an infringement lawsuit, because the U.S. sale exhausts the U.S. patent rights in the product sold. See *ante*, at 1531 – 1536. I dissent, however, from the Court's holding on international exhaustion. A foreign sale, I would hold, does not exhaust a U.S. inventor's U.S. patent rights.

Patent law is territorial. When an inventor receives a U.S. patent, that patent provides no protection abroad. See *Deepsouth Packing Co. v. Laitram Corp.*, 406 U.S. 518, 531, 92 S.Ct. 1700, 32 L.Ed.2d 273 (1972) ("Our patent system makes no claim to extraterritorial effect."). See also 35 U.S.C. § 271(a) (establishing liability for acts of patent infringement "within the United States" and for "import[at]ion into the United States [of] any patented invention"). A U.S. patentee must apply to each country in which she seeks the exclusive right to sell her invention. *Microsoft Corp. v. AT & T Corp.*, 550 U.S. 437, 456, 127 S.Ct. 1746, 167 L.Ed.2d 737 (2007) ("[F]oreign law alone, not United States law, currently governs the manufacture and sale of components of patented inventions in foreign countries."). See also Convention at Brussels, An Additional Act \*1539 Modifying the Paris Convention for the Protection of Industrial Property of Mar. 20, 1883, Dec. 14, 1900, Art. I, 32 Stat. 1940 ("Patents applied for in the different contracting States ... shall be independent of the patents obtained for the same invention in the other States."). And patent laws vary by country; each country's laws "may embody different policy judgments about the relative rights of inventors, competitors, and the public in patented inventions." *Microsoft*, 550 U.S., at 455, 127 S.Ct. 1746 (internal quotation marks omitted).

Because a sale abroad operates independently of the U.S. patent system, it makes little sense to say that such a sale exhausts an inventor's U.S. patent rights. U.S. patent protection accompanies none of a U.S. patentee's sales abroad—a competitor could sell the same patented

product abroad with no U.S.-patent-law consequence. Accordingly, the foreign sale should not diminish the protections of U.S. law in the United States.

The majority disagrees, in part because this Court decided, in *Kirtsaeng v. John Wiley & Sons, Inc.*, 568 U.S. 519, 525, 133 S.Ct. 1351, 185 L.Ed.2d 392 (2013), that a foreign sale exhausts U.S. *copyright* protections. Copyright and patent exhaustion, the majority states, “share a strong similarity.” *Ante*, at 1536 (internal quotation marks omitted). I dissented from our decision in *Kirtsaeng* and adhere to the view that a foreign sale should not exhaust U.S. *copyright* protections. See 568 U.S., at 557, 133 S.Ct. 1351.

But even if I subscribed to *Kirtsaeng*'s reasoning with respect to copyright, that decision should bear little weight in the patent context. Although there may be a “historical kinship” between patent law and copyright law, *Sony Corp. of America v. Universal City Studios, Inc.*, 464 U.S. 417, 439, 104 S.Ct. 774, 78 L.Ed.2d 574 (1984), the two “are not identical twins,” *id.*, at 439, n. 19, 104 S.Ct. 774. The Patent Act contains no analogue

to 17 U.S.C. § 109(a), the Copyright Act first-sale provision analyzed in *Kirtsaeng*. See *ante*, at 1535 – 1536. More importantly, copyright protections, unlike patent protections, are harmonized across countries. Under the Berne Convention, which 174 countries have joined,<sup>\*</sup> members “agree to treat authors from other member countries as well as they treat their own.” *Golan v. Holder*, 565 U.S. 302, 308, 132 S.Ct. 873, 181 L.Ed.2d 835 (2012) (citing Berne Convention for the Protection of Literary and Artistic Works, Sept. 9, 1886, as revised at Stockholm on July 14, 1967, Arts. 1, 5(1), 828 U.N.T.S. 225, 231–233). The copyright protections one receives abroad are thus likely to be similar to those received at home, even if provided under each country's separate copyright regime.

For these reasons, I would affirm the Federal Circuit's judgment with respect to foreign exhaustion.

#### All Citations

137 S.Ct. 1523, 198 L.Ed.2d 1, 85 USLW 4279, 122 U.S.P.Q.2d 1605, 17 Cal. Daily Op. Serv. 4867, 2017 Daily Journal D.A.R. 4923, 26 Fla. L. Weekly Fed. S 599

#### Footnotes

- \* The syllabus constitutes no part of the opinion of the Court but has been prepared by the Reporter of Decisions for the convenience of the reader. See *United States v. Detroit Timber & Lumber Co.*, 200 U.S. 321, 337, 26 S.Ct. 282, 50 L.Ed. 499.
- \* See WIPO–Administered Treaties: Contracting Parties: Berne Convention, [www.wipo.int/treaties/en/ShowResults.jsp?lang=en&treaty\\_id=5](http://www.wipo.int/treaties/en/ShowResults.jsp?lang=en&treaty_id=5) (as last visited May 25, 2017).

137 S.Ct. 734  
Supreme Court of the United States

LIFE TECHNOLOGIES  
CORPORATION et al., Petitioners

v.  
PROMEGA CORPORATION.

No. 14–1538.

|  
Argued Dec. 6, 2016.

|  
Decided Feb. 22, 2017.

### Synopsis

**Background:** Exclusive licensee of patents directed toward process for examining polymorphism in samples of deoxyribonucleic acid (DNA) brought infringement action against sublicensee, which manufactured genetic testing toolkits abroad. The United States District Court for the Western District of Wisconsin, [Barbara Brandriff Crabb, J., 2002 WL 32359938](#), granted licensee's motion to reconsider the claim construction, and later, [2012 WL 12862829](#), granted sublicensee's motion for judgment as matter of law (JMOL) that its accused toolkits were not infringing after jury verdict in licensee's favor. Parties appealed. The United States Court of Appeals for the Federal Circuit, [Chen](#), Circuit Judge, [773 F.3d 1338](#), affirmed in part, reversed in part, vacated in part, and remanded. Certiorari was granted.

**Holdings:** The Supreme Court, Justice [Sotomayor](#), held that:

[1] quantitative measurement rather than qualitative measurement is used when determining whether an alleged infringer has supplied a substantial portion of the components of a patented invention for combination abroad, as basis for liability for active inducement of patent infringement;

[2] a single component of a multicomponent invention does not constitute a substantial portion of the components; and

[3] sublicensee, which supplied from the United States only a single component for the five-component genetic testing toolkits, was not liable for infringement.

Reversed and remanded.

Justice [Alito](#) filed an opinion concurring in part and concurring in the judgment, in which Justice Thomas joined.

Chief Justice Roberts took no part in the decision of the case.

### \*736 Syllabus \*

Respondent Promega Corporation sublicensed the Tautz patent, which claims a toolkit for genetic testing, to petitioner Life Technologies Corporation and its subsidiaries (collectively Life Technologies) for the manufacture and sale of the kits for use in certain licensed law enforcement fields worldwide. One of the kit's five components, an enzyme known as the *Taq* polymerase, was manufactured by Life Technologies in the United States and then shipped to the United Kingdom, where the four other components were made, for combination there. When Life Technologies began selling the kits outside the licensed fields of use, Promega sued, claiming that patent infringement liability was triggered under § 271(f)(1) of the Patent Act, which prohibits the supply from the United States of “all or a substantial portion of the components of a patented invention” for combination abroad. The jury returned a verdict for Promega, but the District Court granted Life Technologies' motion for judgment as a matter of law, holding that § 271(f)(1)'s phrase “all or a substantial portion” did not encompass the supply of a single component of a multicomponent invention. The Federal Circuit reversed. It determined that a single important component could constitute a “substantial portion” of the components of an invention under § 271(f)(1) and found the *Taq* polymerase to be such a component.

*Held* : The supply of a single component of a multicomponent invention for manufacture abroad does not give rise to § 271(f)(1) liability. Pp. 739 – 743.

(a) [Section 271\(f\)\(1\)](#)'s phrase “substantial portion” refers to a quantitative measurement. Although the Patent Act itself does not define the term “substantial,” and the term's ordinary meaning may refer either to qualitative importance or to quantitatively large size, the statutory context points to a quantitative meaning. Neighboring words “all” and “portion” convey a quantitative meaning, and nothing in the neighboring text points to a qualitative interpretation. Moreover, a qualitative reading would render the modifying phrase “of the components” unnecessary the first time it is used in [§ 271\(f\)\(1\)](#). Only the quantitative approach thus gives meaning to each statutory provision.

Promega's proffered “case-specific approach,” which would require a factfinder to decipher whether the components at issue are a “substantial portion” under either a qualitative or a quantitative test, is rejected. Tasking juries with interpreting the statute's meaning on an ad hoc basis would only compound, not resolve, the statute's ambiguity. And Promega's proposal to adopt an analytical framework that accounts for both the components' quantitative and qualitative aspects is likely to complicate rather than aid the factfinder's review. Pp. 739 – 741.

(b) Under a quantitative approach, a single component cannot constitute a “substantial portion” triggering [§ 271\(f\)\(1\)](#) liability. This conclusion is reinforced by [§ 271\(f\)](#)'s text, context, and structure. [Section 271\(f\)\(1\)](#) consistently refers to the plural “components,” indicating that multiple components make up the substantial portion. Reading [§ 271\(f\)\(1\)](#) to cover any single component would also leave little room for [§ 271\(f\)\(2\)](#), which refers to “any component,” and would undermine [§ 271\(f\)\(2\)](#)'s express reference to a single component “especially made or especially adapted for use in the invention.” The \*737 better reading allows the two provisions to work in tandem and gives each provision its unique application. Pp. 741 – 743.

(c) The history of [§ 271\(f\)](#) further bolsters this conclusion. Congress enacted [§ 271\(f\)](#) in response to *Deepsouth Packing Co. v. Laitram Corp.*, 406 U.S. 518, 92 S.Ct. 1700, 32 L.Ed.2d 273, to fill a gap in the enforceability of patent rights by reaching components that are manufactured in the United States but assembled overseas. Consistent with Congress's intent, a supplier may be liable under [§ 271\(f\)\(1\)](#) for supplying from the United States all or a substantial

portion of the components of the invention or under [§ 271\(f\)\(2\)](#) for supplying a single component if it is especially made or especially adapted for use in the invention and not a staple article or commodity. But, as here, when a product is made abroad and all components but a single commodity article are supplied from abroad, the activity is outside the statute's scope. Pp. 742 – 743.

[773 F.3d 1338](#), reversed and remanded.

[SOTOMAYOR](#), J., delivered the opinion of the Court, in which [KENNEDY](#), [GINSBURG](#), [BREYER](#), and [KAGAN](#), JJ., joined, and in which [THOMAS](#) and [ALITO](#), JJ., joined as to all but Part II–C. [ALITO](#), J., filed an opinion concurring in part and concurring in the judgment, in which [THOMAS](#), J., joined. [ROBERTS](#), C.J., took no part in the decision of the case.

#### Attorneys and Law Firms

[Carter G. Phillips](#), Washington, DC, for Petitioners.

[Zachary D. Tripp](#), for the United States as amicus curiae, by special leave of the Court.

[Seth P. Waxman](#), Washington, DC, for Respondent.

[Robert N. Hochman](#), Sidley Austin LLP, Chicago, IL, [Carter G. Phillips](#), Erika L. Maley, Sidley Austin LLP, Washington, DC, for Petitioners.

[Mark C. Fleming](#), Eric F. Fletcher, [Janine M. Lopez](#), Wilmer Cutler Pickering, Hale and Dorr LLP, Boston, MA, [Seth P. Waxman](#), Thomas G. Saunders, [Kevin M. Lamb](#), Wilmer Cutler Pickering, Hale and Dorr LLP, Washington, DC, for Respondent.

#### Opinion

Justice [SOTOMAYOR](#) delivered the opinion of the Court.

This case concerns the intersection of international supply chains and federal patent law. Section 271(f)(1) of the Patent Act of 1952 prohibits the supply from the United States of “all or a substantial portion” of the components of a patented invention for combination abroad. [35 U.S.C. § 271\(f\)\(1\)](#). We granted certiorari to determine whether a party that supplies a single component of a multicomponent invention for manufacture abroad can be held liable for infringement under [§ 271\(f\)\(1\)](#). [579 U.S.](#)

—, 136 S.Ct. 2505, 195 L.Ed.2d 838 (2016). We hold that a single component does not constitute a substantial portion of the components that can give rise to liability under § 271(f)(1). Because only a single component of the patented invention at issue here was supplied from the United States, we reverse and remand.

## I

## A

We begin with an overview of the patent in dispute. Although the science behind \*738 the patent is complex, a basic understanding suffices to resolve the question presented by this case.

The Tautz patent, U.S. Reissue Patent No. RE 37,984, claims a toolkit for genetic testing.<sup>1</sup> The kit is used to take small samples of genetic material—in the form of nucleotide sequences that make up the molecule deoxyribonucleic acid (commonly referred to as “DNA”)—and then synthesize multiple copies of a particular nucleotide sequence. This process of copying, known as amplification, generates DNA profiles that can be used by law enforcement agencies for forensic identification and by clinical and research institutions around the world. For purposes of this litigation, the parties agree that the kit covered by the Tautz patent contains five components: (1) a mixture of primers that mark the part of the DNA strand to be copied; (2) nucleotides for forming replicated strands of DNA; (3) an enzyme known as *Taq* polymerase; (4) a buffer solution for the amplification; and (5) control DNA.<sup>2</sup>

Respondent Promega Corporation was the exclusive licensee of the Tautz patent. Petitioner Life Technologies Corporation manufactured genetic testing kits.<sup>3</sup> During the timeframe relevant here, Promega sublicensed the Tautz patent to Life Technologies for the manufacture and sale of the kits for use in certain licensed law enforcement fields worldwide. Life Technologies manufactured all but one component of the kits in the United Kingdom. It manufactured that component—the *Taq* polymerase—in the United States. Life Technologies shipped the *Taq* polymerase to its United Kingdom facility, where it was combined with the other four components of the kit.

Four years into the agreement, Promega sued Life Technologies on the grounds that Life Technologies had infringed the patent by selling the kits outside the licensed fields of use to clinical and research markets. As relevant here, Promega alleged that Life Technologies' supply of the *Taq* polymerase from the United States to its United Kingdom manufacturing facilities triggered liability under § 271(f)(1).

## B

At trial, the parties disputed the scope of § 271(f)(1)'s prohibition against supplying all or a substantial portion of the components of a patented invention from the United States for combination abroad. Section 271(f)(1)'s full text reads:

“Whoever without authority supplies or causes to be supplied in or from the United States all or a substantial portion of the components of a patented invention, where such components are uncombined in whole or in part, in such manner as to actively induce the combination of such components outside of the United States in a manner that would infringe the patent if such combination occurred within the United States, shall be liable as an infringer.”

\*739 The jury returned a verdict for Promega, finding that Life Technologies had willfully infringed the patent. Life Technologies then moved for judgment as a matter of law, contending that § 271(f)(1) did not apply to its conduct because the phrase “all or a substantial portion” does not encompass the supply of a single component of a multicomponent invention.

The District Court granted Life Technologies' motion. The court agreed that there could be no infringement under § 271(f)(1) because Promega's evidence at trial “showed at most that *one* component of all of the accused products, [the *Taq* ] polymerase, was supplied from the United States.” 2012 WL 12862829, \*3 (W.D.Wis., Sept.

13, 2012) (Crabb, J.). Section 271(f)(1)'s reference to “a substantial portion of the components,” the District Court ruled, does not embrace the supply of a single component. *Id.*, at \*5.

The Court of Appeals for the Federal Circuit reversed and reinstated the jury's verdict finding Life Technologies liable for infringement.<sup>4</sup> 773 F.3d 1338, 1353 (2014). As relevant here, the court held that “there are circumstances in which a party may be liable under § 271(f)(1) for supplying or causing to be supplied a single component for combination outside the United States.” *Ibid.* The Federal Circuit concluded that the dictionary definition of “substantial” is “important” or “essential,” which it read to suggest that a single important component can be a “‘substantial portion of the components’” of a patented invention. *Ibid.* Relying in part on expert trial testimony that the *Taq* polymerase is a “‘main’” and “‘major’” component of the kits, the court ruled that the single *Taq* polymerase component was a substantial component as the term is used in § 271(f)(1). *Id.*, at 1356.

## II

The question before us is whether the supply of a single component of a multicomponent invention is an infringing act under 35 U.S.C. § 271(f)(1). We hold that it is not.

### A

[1] The threshold determination to be made is whether § 271(f)(2)'s requirement of “a substantial portion” of the components of a patented invention refers to a quantitative or qualitative measurement. Life Technologies and the United States argue that the text of § 271(f)(1) establishes a quantitative threshold, and that the threshold must be greater than one. Promega defends the Federal Circuit's reading of the statute, arguing that a “substantial portion” of the components includes a single component if that component is sufficiently important to the invention.

We look first to the text of the statute. *Sebelius v. Cloer*, 569 U.S. —, —, 133 S.Ct. 1886, 1892–1893, 185 L.Ed.2d 1003 (2013). The Patent Act itself does not define the term “substantial,” and so we turn to its ordinary

meaning. *Ibid.* Here we find little help. All agree the term is ambiguous and, taken in isolation, might refer to an important portion or to a large portion. Brief for Petitioners 16; Brief for Respondent 18; Brief for United States as *Amicus Curiae* 12. “Substantial,” as it is commonly understood, may refer either to qualitative importance or to \*740 quantitatively large size. See, e.g., Webster's Third New International Dictionary 2280 (defs. 1c, 2c) (1981) (Webster's Third) (“important, essential,” or “considerable in amount, value, or worth”); 17 Oxford English Dictionary 67 (defs. 5a, 9) (2d ed. 1989) (OED) (“That is, constitutes, or involves an essential part, point, or feature; essential, material,” or “Of ample or considerable amount, quantity, or dimensions”).

[2] The context in which “substantial” appears in the statute, however, points to a quantitative meaning here. Its neighboring terms are the first clue. “[A] word is given more precise content by the neighboring words with which it is associated.” *United States v. Williams*, 553 U.S. 285, 294, 128 S.Ct. 1830, 170 L.Ed.2d 650 (2008). Both “all” and “portion” convey a quantitative meaning. “All” means the entire quantity, without reference to relative importance. See, e.g., Webster's Third 54 (defs. 1a, 2a, 3) (“that is the whole amount or quantity of,” or “every member or individual component of,” or “the whole number or sum of”); 1 OED 324 (def. 2) (“The entire number of; the individual components of, without exception”). “Portion” likewise refers to some quantity less than all. Webster's Third 1768 (defs. 1, 3a) (“an individual's part or share of something,” or “a part of a whole”); 12 OED 154, 155 (def. 1a, 5a) (“The part (of anything) allotted or belonging to one person,” or “A part of any whole”). Conversely, there is nothing in the neighboring text to ground a qualitative interpretation.

[3] Moreover, the phrase “substantial portion” is modified by “of the components of a patented invention.” It is the supply of all or a substantial portion “of the components” of a patented invention that triggers liability for infringement. But if “substantial” has a qualitative meaning, then the more natural way to write the opening clause of the provision would be to not reference “the components” at all. Instead, the opening clause of § 271(f)(1) could have triggered liability for the supply of “all or a substantial portion of ... a patented invention, where [its] components are uncombined in whole or in part.” A qualitative reading would render the phrase “of the components” unnecessary the first time it is used in §

[271\(f\)\(1\)](#). Whenever possible, however, we should favor an interpretation that gives meaning to each statutory provision. See [Hibbs v. Winn](#), 542 U.S. 88, 101, 124 S.Ct. 2276, 159 L.Ed.2d 172 (2004). Only the quantitative approach does so here. Thus, “substantial,” in the context of [§ 271\(f\)\(1\)](#), is most reasonably read to connote a quantitative measure.

Promega argues that a quantitative approach is too narrow, and invites the Court to instead adopt a “case-specific approach” that would require a factfinder to decipher whether the components at issue are a “substantial portion” under *either* a qualitative or quantitative test. Brief for Respondent 17, 42. We decline to do so. Having determined the phrase “substantial portion” is ambiguous, our task is to resolve that ambiguity, not to compound it by tasking juries across the Nation with interpreting the meaning of the statute on an ad hoc basis. See, e.g., [Robinson v. Shell Oil Co.](#), 519 U.S. 337, 345–346, 117 S.Ct. 843, 136 L.Ed.2d 808 (1997).

As a more general matter, moreover, we cannot accept Promega's suggestion that the Court adopt a different analytical framework entirely—one that accounts for both the quantitative *and* qualitative aspects of the components. Promega reads [§ 271\(f\)\(1\)](#) to mean that the answer to whether a given portion of the components is “substantial” depends not only on the number of components involved but also on their qualitative importance to the invention \*741 overall. At first blush, there is some appeal to the idea that, in close cases, a subjective analysis of the qualitative importance of a component may help determine whether it is a “substantial portion” of the components of a patent. But, for the reasons discussed above, the statute's structure provides little support for a qualitative interpretation of the term.<sup>5</sup>

Nor would considering the qualitative importance of a component necessarily help resolve close cases. To the contrary, it might just as easily complicate the factfinder's review. Surely a great many components of an invention (if not every component) are important. Few inventions, including the one at issue here, would function at all without any one of their components. Indeed, Promega has not identified any component covered by the Tautz patent that would not satisfy Promega's “importance” litmus test.<sup>6</sup> How are courts—or, for that matter, market participants attempting to avoid liability—to

determine the relative importance of the components of an invention? Neither Promega nor the Federal Circuit offers an easy way to make this decision. Accordingly, we conclude that a quantitative interpretation hews most closely to the text of the statute and provides an administrable construction.

## B

**[4]** **[5]** Having determined that the term “substantial portion” refers to a quantitative measurement, we must next decide whether, as a matter of law, a single component can ever constitute a “substantial portion” so as to trigger liability under [§ 271\(f\)\(1\)](#). The answer is no.

As before, we begin with the text of the statute. [Section 271\(f\)\(1\)](#) consistently refers to “components” in the plural. The section is targeted toward the supply of all or a substantial portion “of the *components*,” where “such *components*” are uncombined, in a manner that actively induces the combination of “such *components*” outside the United States. Text specifying a substantial portion of “components,” plural, indicates that multiple components constitute the substantial portion.

The structure of [§ 271\(f\)](#) reinforces this reading. [Section 271\(f\)\(2\)](#), which is [§ 271\(f\)\(1\)](#)'s companion provision, reads as follows:

“Whoever without authority supplies or causes to be supplied in or from the United States any component of a patented invention that is especially made or especially adapted for use in the invention and not a staple article or commodity of commerce suitable for substantial noninfringing use, where such component is uncombined in whole or in part, knowing that such component is so made or adapted and intending that such component will be combined outside of the United States in a manner that would infringe the patent if such combination occurred within the United States, shall be liable as an infringer.”

Reading § 271(f)(1) to refer to more than one component allows the two provisions \*742 to work in tandem. Whereas § 271(f)(1) refers to “components,” plural, § 271(f)(2) refers to “any component,” singular. And, whereas § 271(f)(1) speaks to whether the components supplied by a party constitute a substantial portion of the components, § 271(f)(2) speaks to whether a party has supplied “any” noncommodity component “especially made or especially adapted for use in the invention.”

We do not disagree with the Federal Circuit's observation that the two provisions concern different scenarios. See 773 F.3d, at 1354. As this Court has previously observed, §§ 271(f)(1) and 271(f)(2) “differ, among other things, on the quantity of components that must be ‘supplie[d] ... from the United States’ for liability to attach.” *Microsoft Corp. v. AT & T Corp.*, 550 U.S. 437, 454, n. 16, 127 S.Ct. 1746, 167 L.Ed.2d 737 (2007). But we do not draw the Federal Circuit's conclusion from these different but related provisions. Reading § 271(f)(1) to cover *any* single component would not only leave little room for § 271(f)(2), but would also undermine § 271(f)(2)'s express reference to a single component “especially made or especially adapted for use in the invention.”<sup>7</sup> Our conclusion that § 271(f)(1) prohibits the supply of components, plural, gives each subsection its unique application.<sup>8</sup> See, e.g., *Cloer*, 569 U.S., at —, 133 S.Ct., at 1892–1893.

Taken alone, § 271(f)(1)'s reference to “components” might plausibly be read to encompass “component” in the singular. See 1 U.S.C. § 1 (instructing that “words importing the plural include the singular,” “unless the context indicates otherwise”). But § 271(f)'s text, context, and structure leave us to conclude that when Congress said “components,” plural, it meant plural, and when it said “component,” singular, it meant singular.

We do not today define how close to “all” of the components “a substantial portion” must be. We hold only that one component does not constitute “all or a substantial portion” of a multicomponent invention under § 271(f)(1). This is all that is required to resolve the question presented.

C

The history of § 271(f) bolsters our conclusion. The Court has previously observed that Congress enacted § 271(f) in response to our decision in *Deepsouth Packing Co. v. Laitram Corp.*, 406 U.S. 518, 92 S.Ct. 1700, 32 L.Ed.2d 273 (1972). See *Microsoft Corp.*, 550 U.S., at 444, 127 S.Ct. 1746. In *Deepsouth*, the Court determined that, under patent law as it existed at the time, it was “not an infringement \*743 to make or use a patented product outside of the United States.” 406 U.S., at 527, 92 S.Ct. 1700. The new § 271(f) “expand[ed] the definition of infringement to include supplying from the United States a patented invention's components,” as outlined in subsections (f)(1) and (f)(2). *Microsoft*, 550 U.S., at 444–445, 127 S.Ct. 1746.

The effect of this provision was to fill a gap in the enforceability of patent rights by reaching components that are manufactured in the United States but assembled overseas and that were beyond the reach of the statute in its prior formulation. Our ruling today comports with Congress' intent. A supplier may be liable under § 271(f)(1) for supplying from the United States all or a substantial portion of the components (plural) of the invention, even when those components are combined abroad. The same is true even for a single component under § 271(f)(2) if it is especially made or especially adapted for use in the invention and not a staple article or commodity. We are persuaded, however, that when as in this case a product is made abroad and all components but a single commodity article are supplied from abroad, this activity is outside the scope of the statute.

### III

We hold that the phrase “substantial portion” in 35 U.S.C. § 271(f)(1) has a quantitative, not a qualitative, meaning. We hold further that § 271(f)(1) does not cover the supply of a single component of a multicomponent invention. The judgment of the Court of Appeals for the Federal Circuit is therefore reversed, and the case is remanded for further proceedings consistent with this opinion.

*It is so ordered.*

THE CHIEF JUSTICE took no part in the decision of this case.

Justice ALITO, with whom Justice THOMAS joins, concurring in part and concurring in the judgment. I join all but Part II–C of the Court's opinion. It is clear from the text of 35 U.S.C. § 271(f) that Congress intended not only to fill the gap created by *Deepsouth Packing Co. v. Laitram Corp.*, 406 U.S. 518, 92 S.Ct. 1700, 32 L.Ed.2d 273 (1972)—where all of the components of the invention were manufactured in the United States, *id.*, at 524, 92 S.Ct. 1700—but to go at least a little further. How much further is the question in this case, and the genesis of § 271(f) sheds no light on that question.

I note, in addition, that while the Court holds that a single component cannot constitute a substantial portion of an invention's components for § 271(f)(1) purposes, I do not read the opinion to suggest that *any* number greater than one is sufficient. In other words, today's opinion establishes that more than one component is necessary, but does not address *how much* more.

#### All Citations

137 S.Ct. 734, 197 L.Ed.2d 33, 85 USLW 4049, 121 U.S.P.Q.2d 1641, 17 Cal. Daily Op. Serv. 1585, 2017 Daily Journal D.A.R. 1566, 26 Fla. L. Weekly Fed. S 434

#### Footnotes

- \* The syllabus constitutes no part of the opinion of the Court but has been prepared by the Reporter of Decisions for the convenience of the reader. See *United States v. Detroit Timber & Lumber Co.*, 200 U.S. 321, 337, 26 S.Ct. 282, 50 L.Ed. 499.
- 1 The Tautz patent expired in 2015. The litigation thus concerns past acts of infringement only.
- 2 Because the parties here agree that the patented invention is made up of only these five components, we do not consider how to identify the “components” of a patent or whether and how that inquiry relates to the elements of a patent claim.
- 3 Applied Biosystems, LLC, and Invitrogen IP Holdings, Inc., are also petitioners in this proceeding and are wholly owned subsidiaries of Life Technologies Corporation. The agreement at issue here was originally between Promega and Applied Biosystems. 773 F.3d 1338, 1344, n. 3 (C.A.Fed.2014).
- 4 Chief Judge Prost dissented from the majority's conclusion with respect to the “active inducement” element of 35 U.S.C. § 271(f)(1). 773 F.3d, at 1358–1360. Neither that question, nor any of the Federal Circuit's conclusions regarding Life Technologies' liability under § 271(a) or infringement of four additional Promega patents, see *id.*, at 1341, is before us. See 579 U.S. —, 136 S.Ct. 2505, 195 L.Ed.2d 838 (2016).
- 5 The examples Promega provides of other statutes' use of the terms “substantial” or “significant” are inapposite. See Brief for Respondent 19–20. The text of these statutes, which arise in different statutory schemes with diverse purposes and structures, differs in material ways from the text of § 271(f)(1). The Tax Code, for instance, refers to “a substantial portion of a return,” 26 U.S.C. § 7701(a)(36)(A), not to “a substantial portion of the entries of a return.”
- 6 Life Technologies' expert described the *Taq* polymerase as a “main” component. App. 160. The expert also described two other components the same way. *Ibid.*
- 7 This Court's opinion in *Microsoft Corp. v. AT & T Corp.*, 550 U.S. 437, 447, 127 S.Ct. 1746, 167 L.Ed.2d 737 (2007), is not to the contrary. The holding in that case turned not on the number of components involved, but rather on whether the software at issue was a component at all.
- 8 Promega argues that the important distinction between these provisions is that § 271(f)(1), unlike § 271(f)(2), requires a showing of specific intent for active inducement. Brief for Respondent 34–41. But cf. *Global–Tech Appliances, Inc. v. SEB S.A.*, 563 U.S. 754, 765–766, 131 S.Ct. 2060, 179 L.Ed.2d 1167 (2011) (substantially equating the intent requirements for §§ 271(b) and 271(c), on which Promega asserts §§ 271(f)(1) and (f)(2) were modeled). But, to repeat, whatever intent subsection (f)(1) may require, it also imposes liability only on a party who supplies a “substantial portion of the components” of the invention. Thus, even assuming that subsection (f)(1)'s “active inducement” requirement is different from subsection (f)(2)'s “knowing” and “intending” element—a question we do not reach today—that difference between the two provisions does not read the “substantial portion” language out of the statute.

NYIPLA  
One-Day Patent CLE Seminar  
November 16, 2017



Licensing Strategies in View of  
*Lexmark* and *Promega*

Speakers: Robert M. Isackson  
Partner, Intellectual Property Litigation  
Venable LLP  
[RMIsackson@Venable.com](mailto:RMIsackson@Venable.com)


Eugene Chang  
Partner, Intellectual Property  
Willkie Farr & Gallagher LLP  
[EChang@Willkie.com](mailto:EChang@Willkie.com)

Moderator: Diana Santos  
Associate, Intellectual Property  
Willkie Farr & Gallagher LLP  
[DSantos@Willkie.com](mailto:DSantos@Willkie.com)

*Arizona Cartridge Remanufacturers Ass'n,  
Inc. v. Lexmark* : License Language

RETURN EMPTY CARTRIDGE TO LEXMARK FOR  
REMANUFACTURING AND RECYCLING

Please read before opening. Opening of this package or using the patented cartridge inside confirms your acceptance of the following license agreement. The patented cartridge is sold at a special price subject to a restriction that it may be used only once. Following this initial use, you agree to return the empty cartridge only to Lexmark for remanufacturing and recycling. If you don't accept these terms, return the unopened package to your point of purchase. A regular price cartridge without these terms is available.





## Lexmark: Permitted Sales, Territory & Patent Exhaustion

- “We conclude that a patentee’s decision to sell a product exhausts all of its patent rights in that item, regardless of any restrictions the patentee purports to impose or the location of the sale.”
- “So long as a licensee complies with the license when selling an item, the patentee has, in effect, authorized the sale. That licensee’s sale is treated for purposes of patent exhaustion, as if the patentee made the sale itself.”
- “An authorized sale outside the United States, just as one within the United States, exhausts all rights under the Patent Act.”
- “The single-use/no-resale restrictions in Lexmark’s contracts may have been clear and enforceable under contract law, but they do not entitle Lexmark to retain *patent rights* in an item it has elected to sell.” (emphasis added)

*Impression Prods., Inc. v. Lexmark Int’l, Inc.*,  
137 S.Ct. 1523, 1529, 1535, 1531 (2017).

## Promega: Substantial Portion



- “Having determined that the term ‘substantial portion’ refers to a quantitative measurement, we must next decide whether, as a matter of law, a single component can ever constitute a ‘substantial portion’ so as to trigger liability under §271(f)(1). The answer is no.”

*Life Techs. Corp. v. Promega Corp.*, 137 S.Ct. 724, 741 (2017).



(19) United States

(12) Reissued Patent  
Jäckle et al.

(10) Patent Number: US RE37,984 E

(45) Date of Reissued Patent: Feb. 11, 2003

(54) PROCESS FOR ANALYZING LENGTH  
POLYMORPHISMS IN DNA REGIONS

H. Chen et al., *Human Mutation*, 4:208-211 (1994).  
X. Y. Huang et al., *Human Molecular Genetics*,  
2(9):411-415 (1993).

- “I note, in addition, that while the Court holds that a single component cannot constitute a substantial portion of an invention’s components for §271(f)(1) purposes, I do not read the opinion to suggest that any number greater than one is sufficient. In other words, today’s opinion establishes that more than one component is necessary, but does not address how much more.”

Concurrence (J. Alito).

Thank You.

Questions?